6-chloro-2-iodopurin-9-yl-methyl 2,2-dimethylpropionate | 630103-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-chloro-2-iodopurin-9-yl-methyl 2,2-dimethylpropionate
• 英文别名: (6-Chloro-2-iodopurin-9-yl)methyl 2,2-dimethylpropanoate
• CAS: 630103-54-7
• 化学式: C₁₁H₁₂ClIN₄O₂
• 分子量: 394.599
• InChiKey: USYBBWJHQLJASU-UHFFFAOYSA-N

物化性质

• 沸点：
  499.0±55.0 °C(Predicted)
• 密度：
  1.86±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  69.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-2-iodopurin-9-yl-methyl 2,2-dimethylpropionate 在 sodium hydroxide 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 147.0h， 生成 (1'R,2'S,4'S,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxyphosphoryloxymethyl)-4-(2-iodo-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl ester
  参考文献：
  名称：

  2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation:  Enhanced Potency as P2Y₁ Receptor Antagonists

  摘要：

  Preference for the northern (N) ring conformation of the ribose moiety of adenine nucleotide 3',5'-bisphosphate antagonists of P2Y(1), receptors was established by using a ring-constrained methanocarba (a bicyclo[3.1.0]hexane) ring as a ribose substitute (Nandanan et al. J. Med. Chem. 2000, 43, 829-842). We have now combined the ring-constrained (N)-methanocarba modification with other functionalities at the 2-position of the adenine moiety. A new synthetic route to this series of bisphosphate derivatives was introduced, consisting of phosphorylation of the pseudoribose moiety prior to coupling with the adenine base. The activity of the newly synthesized analogues was determined by measuring antagonism of 2-methylthio-ADP-stimulated phospholipase C (PLC) activity in 1321N1 human astrocytoma cells expressing the recombinant human P2Y(1), receptor and by using the radiolabeled antagonist [H-3](2)-chloro-N-6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bisphosphate 5 in a newly developed binding assay in Sf9 cell membranes. Within the series of 2-halo analogues, the most potent molecule at the hP2Y(1) receptor was an (N)-methanocarba N-6-methyl-2-iodo analogue 12, which displayed a K-i value in competition for binding of [H-3]5 of 0.79 nM and a K-B value of 1.74 nM for inhibition of PLC. Thus, 12 is the most potent antagonist selective for the P2Y(1), receptor yet reported. The 2-iodo group was substituted with trimethyltin, thus providing a parallel synthetic route for the introduction of an iodo group in this high-affinity antagonist. The (N)-methanocarba-2-methylthio, 2-methylseleno, 2-hexyl, 2-(1-hexenyl), and 2-(l-hexynyl) analogues bound less well, exhibiting micromolar affinity at P2Y(1), receptors. An enzymatic method of synthesis of the 3',5'-bisphosphate from the corresponding 3'-monophosphate, suitable for the preparation of a radiophosphorylated analogue, was explored.

  DOI：

  10.1021/jm030127+
• 作为产物：
  描述：

  2-amino-6-chloropurin-9-yl-methyl 2,2-dimethylpropionate 在 copper(l) iodide 、 二碘甲烷 、 碘 、 亚硝酸异戊酯 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以65%的产率得到6-chloro-2-iodopurin-9-yl-methyl 2,2-dimethylpropionate
  参考文献：
  名称：

  嘌呤-2-基和嘌呤-6-基-氨基葡萄糖醇的合成（作为C-核苷ATP模拟物）和作为FGFR3抑制剂的生物学评估

  摘要：

  已经使用一种有效且通用的合成途径合成了两个新系列的C-核苷ATP模拟物。使用嘌呤作为中心支架，将这些化合物设计为FGFR3抑制剂。为了研究任何可能的结合方式，两个取代基，即多羟基化的核糖模拟物和亲脂性部分，在嘌呤环的2或6位连接。所有化合物都能够在浓度为50μM的情况下抑制FGFR3激酶活性。出乎意料的是，发现最好的抑制剂是位置2上带有碘原子的合成中间体13之一。对接研究证实了其在ATP结合位点的位置，并揭示了关键相互作用之间的卤素键。

  DOI：

  10.1016/j.ejmech.2011.01.048

文献信息

• Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-α-threofuranosyl ring systems: interactions with P2Y receptors
  作者：Michihiro Ohno、Stefano Costanzi、Hak Sung Kim、Veerle Kempeneers、Karen Vastmans、Piet Herdewijn、Savitri Maddileti、Zhan-Guo Gao、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1016/j.bmc.2004.07.067

  日期：2004.11

  5'-bisphosphate antagonists of the P2Y(1) receptor has been successfully substituted with a rigid methanocarba ring system, leading to the conclusion that the North (N) ring conformation is preferred in receptor binding. Similarly, at P2Y(2) and P2Y(4) receptors, nucleotides constrained in the (N) conformation interact equipotently with the corresponding ribosides. We now have synthesized and examined

  P2Y（1）受体的腺嘌呤核苷酸3'，5'-二磷酸拮抗剂的核糖部分已成功地被刚性的甲烷甲环系统取代，从而得出结论，在受体结合中优选North（N）环构象。类似地，在P2Y（2）和P2Y（4）受体上，受约束于（N）构象的核苷酸与相应的核苷等位相互作用。我们现在已经合成并检查了被两个新的环系统取代的P2Y受体配体核苷酸类似物：（1）含氧杂双环[2.2.1]庚烷环系统的（N）锁碳环（cLNA）衍生物和（2）l- α-苏呋喃糖基衍生物。我们还比较了这些核苷酸与已知的含脱水己糖醇的P2Y（1）受体拮抗剂MRS2283的效力和优选构象。cLNA双磷酸酯衍生物MRS2584 21在与人P2Y（1）受体结合时显示22.5 nM的K（i）值，并与强效P2Y（1）受体激动剂2-甲硫基ADP（30 nM ），IC（50）为650 nM。亲本cLNA核苷仅弱绑定到腺苷受体（A（3））。因此，该环系统提供了一些P2Y
• P2Y₁ Antagonists:  Combining Receptor-Based Modeling and QSAR for a Quantitative Prediction of the Biological Activity Based on Consensus Scoring
  作者：Stefano Costanzi、Irina G. Tikhonova、Michihiro Ohno、Eun Joo Roh、Bhalchandra V. Joshi、Anny-Odile Colson、Dayle Houston、Savitri Maddileti、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/jm0700971

  日期：2007.7.1

  P2Y(1) is an ADP-activated G protein-coupled receptor (GPCR). Its antagonists impede platelet aggregation in vivo and are potential antithrombotic agents. Combining ligand and structure-based modeling we generated a consensus model (LIST-CM) correlating antagonist structures with their potencies. We docked 45 antagonists into our rhodopsin-based human P2Y(1) homology model and calculated docking scores and free binding energies with the Linear Interaction Energy (LIE) method in continuum-solvent. The resulting alignment was also used to build QSAR based on CoMFA, CoMSIA, and molecular descriptors. To benefit from the strength of each technique and compensate for their limitations, we generated our LIST-CM with a PLS regression based on the predictions of each methodology. A test set featuring untested substituents was synthesized and assayed in inhibition of 2-MeSADP-stimulated PLC activity and in radioligand binding. LIST-CM outperformed internal and external predictivity of any individual model to predict accurately the potency of 75% of the test set.